Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel

Nu-3 is described as a gel formulation of a Bisphosphocin® compound aimed at topical treatment of infected diabetic foot ulcers, with a low likelihood of systemic side effects. The article provides no efficacy, trial, or commercialization metrics, so incremental market impact is likely limited.

Analysis

Nu-3 is described as a gel formulation of a Bisphosphocin® compound aimed at topical treatment of infected diabetic foot ulcers, with a low likelihood of systemic side effects. The article provides no efficacy, trial, or commercialization metrics, so incremental market impact is likely limited.